Back to Search Start Over

Rituximab as an effective therapeutic option in refractory Neuro-Behçet syndrome.

Authors :
Garcia-Estrada C
Casallas-Vanegas A
Zabala-Angeles I
Gomez-Figueroa E
Rivas-Alonso V
Flores-Rivera J
Source :
Journal of neuroimmunology [J Neuroimmunol] 2020 Jun 26; Vol. 346, pp. 577308. Date of Electronic Publication: 2020 Jun 26.
Publication Year :
2020
Publisher :
Ahead of Print

Abstract

Introduction: Behçet's disease (BD) is an inflammatory disease of unknown etiology with periods of relapses and remissions. Neuro-Behçet syndrome (NBS) is one of the main causes of long-term morbidity and mortality, making its prompt recognition and early treatment fundamental to achieving a better outcome. Currently there are no treatment guidelines either for BS or NB, making the management of these patients particularly difficult.<br />Case Presentation: We present the case report of a patient with pseudo-tumoral lesion and myelitis refractory to steroids and cyclophosphamide who successfully showed remission after treatment with an anti-CD20 therapy.<br />Conclusion: This is the first report of concomitant pseudo-tumoral lesion and myelitis secondary to BS. We found rituximab treatment to be a safe and effective therapeutic option for NB supported by the radiological and clinical improvement achieved in our patient.<br />Competing Interests: Declaration of Competing Interest All authors declare no competing interests or external funding.<br /> (Copyright © 2020 Elsevier B.V. All rights reserved.)

Details

Language :
English
ISSN :
1872-8421
Volume :
346
Database :
MEDLINE
Journal :
Journal of neuroimmunology
Publication Type :
Academic Journal
Accession number :
32619893
Full Text :
https://doi.org/10.1016/j.jneuroim.2020.577308